Methinks AI

Methinks operates in the clinical AI and medical-imaging segment, focusing on stroke triage rather than general-purpose radiology. Its Methinks Stroke Suite analyzes non-contrast CT, CT angiography, and intracranial hemorrhage images to support detection of large vessel occlusions and hemorrhage, while its workflow tools aim to coordinate stroke teams. Website details specify that its non-contrast CT LVO product is designed to detect occlusions as far as the M2 segment. Microsoft Teams integration, real-time alerts, secure messaging, cross-hospital calls, image review, and access to AI results distinguish the offering as a combination of image analysis and care-team coordination. The 2026 Neuro-rescue initiative extends that approach into telemedicine for emergency departments without on-site neurological specialists. Its competitive context is therefore best described by the problem it addresses: helping hospitals interpret time-sensitive stroke imaging and coordinate care across sites. CE Mark certification, announced in 2023, is a relevant regulatory milestone, while the 2025 Done Symple trial and 2026 Vithas deployment plans indicate clinical and implementation activity. The company is private and has reported grant, convertible-note, and seed financing rather than a disclosed large institutional equity round.

Methinks’ reported financing totals $7,666,690 across four rounds, with the total drawn from structured company data. The funding history includes a seed round in 2020 with no disclosed amount, a €2.5 million grant in October 2022, a €2.5 million convertible note in November 2023, and a €2.19 million grant announced on Apr 13, 2026. The 2026 grant is the latest recorded financing and supports work on early detection of neurological conditions in emergency departments. Product development also shows expansion in scope: the company’s core stroke software analyzes CT and CT angiography images, while Neuro-rescue adds telemedicine links to remote radiologists and neurologists. The 2026 announcement described initial deployment in several Vithas hospitals and a consortium involving Fundación Vithas, Fundació Món Clínic, and Atrys. Earlier signals include CE Mark certification announced in February 2023, a reported role for Methinks AI in the Done Symple trial in April 2025, and a January 2025 report on stroke diagnosis at Hospital General de Granollers. The company is listed in the 11–50 employee range and reports active recruiting, though no specific hiring functions are identified. The clearest growth inflection is the move from developing and certifying stroke-triage software toward broader emergency-neurology services delivered with hospital and telemedicine partners.